This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Delinia, Inc.. Active years: 2019-2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019-2021
Title: Jungmin Kim: Innovator in Regulatory T Cell Modulation
Introduction
Jungmin Kim is a prominent inventor based in Berkeley, CA (US). He has made significant contributions to the field of immunology, particularly in the development of regulatory T cell modulators. With a total of 2 patents to his name, his work is paving the way for innovative treatments in this area.
Latest Patents
Jungmin Kim's latest patents focus on multivalent regulatory T cell modulators. These disclosures provide compounds that contain an IL-2 receptor-binding moiety and an ST2-binding moiety. The methods described in these patents offer a therapeutic approach for treating conditions by administering a therapeutically effective amount of these compounds to subjects in need.
Career Highlights
Jungmin Kim is currently associated with Delinia, Inc., where he continues to advance his research and development efforts. His work is instrumental in exploring new avenues for immunotherapy and enhancing the efficacy of treatments.
Collaborations
Some of his notable coworkers include Jeffrey M Greve and Niranjana Aditi Nagarajan. Their collaborative efforts contribute to the innovative environment at Delinia, Inc., fostering advancements in the field.
Conclusion
Jungmin Kim's contributions to the field of regulatory T cell modulation highlight his role as an influential inventor. His patents and ongoing research are set to make a significant impact on therapeutic strategies in immunology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile